Insider Selling: Bolt Biotherapeutics (NASDAQ:BOLT) CEO Sells $29,587.68 in Stock

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) CEO William Quinn sold 9,132 shares of the company’s stock in a transaction on Friday, September 18th. The shares were sold at an average price of $3.24, for a total value of $29,587.68. Following the completion of the transaction, the chief executive officer owned 25,384 shares of the company’s stock, valued at $82,244.16. This trade represents a 26.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Bolt Biotherapeutics Trading Down 1.6%

NASDAQ BOLT opened at $3.65 on Thursday. The stock has a market capitalization of $7.04 million, a price-to-earnings ratio of -0.22 and a beta of 1.09. Bolt Biotherapeutics, Inc. has a one year low of $3.10 and a one year high of $7.20. The company has a debt-to-equity ratio of 1.47, a current ratio of 2.61 and a quick ratio of 2.61. The business’s fifty day moving average is $3.82 and its 200-day moving average is $4.28.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($4.57) earnings per share for the quarter, missing the consensus estimate of ($3.39) by ($1.18). The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.50 million. Bolt Biotherapeutics had a negative net margin of 611.47% and a negative return on equity of 126.23%. Equities research analysts predict that Bolt Biotherapeutics, Inc. will post -11.1 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of BOLT. Nan Fung Group Holdings Ltd purchased a new stake in shares of Bolt Biotherapeutics during the second quarter worth $19,250. Renaissance Technologies LLC grew its position in shares of Bolt Biotherapeutics by 40.3% in the first quarter. Renaissance Technologies LLC now owns 77,225 shares of the company’s stock valued at $312,000 after purchasing an additional 22,200 shares in the last quarter. Finally, T3 Companies LLC bought a new stake in shares of Bolt Biotherapeutics during the 4th quarter valued at $208,000. 86.70% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

BOLT has been the topic of several research analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Friday, July 17th. HC Wainwright restated a “buy” rating and issued a $7.00 target price on shares of Bolt Biotherapeutics in a research note on Thursday, May 28th. Finally, Rodman & Renshaw started coverage on Bolt Biotherapeutics in a research report on Thursday, May 28th. They set a “buy” rating and a $22.00 price target on the stock. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Bolt Biotherapeutics presently has a consensus rating of “Hold” and an average price target of $14.50.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s platform is designed to stimulate the body’s innate and adaptive immune systems to recognize and attack tumor cells.

Bolt’s technology includes Boltbody™ immune-stimulating antibody conjugates, or ISACs. These therapies are intended to combine the targeting capabilities of antibodies with immune-activating components that can recruit and enhance the activity of immune cells within the tumor microenvironment.

The company’s development programs have included BDC-1001, an investigational HER2-targeted ISAC for the treatment of HER2-expressing solid tumors, and BDC-3042, an investigational antibody intended to activate macrophages through the Dectin-2 pathway.